dm+d

Unassigned

New Medicines

Serious gram-negative bacterial infections in adults

Information

New formulation
Pfizer
AbbVie

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

A fixed dose combination of avibactam (a monobactam) and aztreonam (a non-beta-lactam beta-lactamase inhibitor)
In 2017/18 there were around 180000 hospital admissions for cUTIs, sepsis and pneumonia due to gram negative bacteria. [5] It is estimated that around 10% of currently available antibiotics are resistant to these bacteria [6] so around18,000 people could require antibiotics reserved for resistant infections, so around 11 per 100,000 people in England may be eligible for this.
Serious gram-negative bacterial infections in adults
Intravenous infusion